* 中国生物技术公司--派格生物医药2565.HK周二香港首日挂牌开低17%后，盘初扩大跌幅至28%，低探11.22港元。
* 该公司专注于代谢紊乱领域，其自主开发、接近商业化阶段的核心产品PB-119主要用于2型糖尿病及肥胖症一线治疗。
* 是次在香港上市集资3亿港元，招股价为每股15.6港元，公开发售及国际配售分别获744倍及1.1倍认购。（完）
更多股市简讯请点选CN-CMN-HOT
(记者 雷美珍；审校 田镧沁)
((alison.lui@thomsonreuters.com; +852 3462 7749;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.